Table 3.
Results of Cox regression analyses for clinicopathological factors and CXCL16 in stromal cells (model 1) and co-expression of CXCL16 in cancer and stromal cells (model 2*)
| Factor | HR | CI 95 % | P |
|---|---|---|---|
| Tumor stage | <0.001† | ||
| T1 | 1.00 | ||
| T2 | 1.60 | (0.97–2.64) | 0.065 |
| T3 | 3.80 | (2.13–6.77) | <0.001 |
| Nodal stage | <0.001† | ||
| N0 | 1.00 | ||
| N1 | 2.01 | (1.30–3.11) | 0.002 |
| N2 | 3.08 | (1.74–5.44) | <0.001 |
| Differentiation | 0.009† | ||
| Well | 1.00 | ||
| Poor | 1.17 | (1.12–3.85) | 0.020 |
| Moderate | 2.08 | (0.63–2.20) | 0.618 |
| Performance status | 0.040† | ||
| 0 | 1.00 | ||
| 1 | 1.52 | (1.02–2.26) | 0.040 |
| 2 | 2.15 | (0.94–4.91) | 0.069 |
| Vascular infiltration | |||
| No | 1.00 | ||
| Yes | 1.70 | (1.01–2.87) | 0.046 |
| Histology | <0.001† | ||
| Squamous carcinoma | 1.00 | ||
| Adenocarcinoma | 2.23 | (1.48–3.35) | <0.001 |
| Large cell carcinoma | 0.80 | (0.39–1.66) | 0.555 |
| CXC16 stromal cells | |||
| Low | 1 | ||
| High | 0.55 | (0.35–0.87) | 0.011 |
| CXCL16 cancer and stromal cells* | 0.031† | ||
| Low/Low | 1.00 | ||
| Low/High + High/Low | 0.57 | (0.35–0.93) | 0.023 |
| Low/Low | 0.42 | (0.20–0.88) | 0.022 |
†Overall significance as prognostic marker. HR, hazard ratio; CI 95 %, 95 % confidence interval